No Cancer Risk With Insulin Glargine, Says EMANo Cancer Risk With Insulin Glargine, Says EMA
The European Medicines Agency has concluded there is no increased risk of cancer associated with insulin-glargine products. News Alerts
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Diabetes | Endocrinology | European Medicines Agency (EMA) | Health | Insulin | Lantus